“InterHealth supports Lonza’s strategic positioning as high value supplier to the healthcare industry,” Dominik Werner, a Lonza spokesperson told us.
“It broadens Lonza’s nutritional ingredient portfolio and strengthens our position in the dietary supplement market. InterHealth is a strong brand and very well perceived as technologically driven nutraceutical ingredients provider.”
InterHealth’s flagship ingredient is UC-II for join-health, although the company offers more than 15 branded ingredients.
According to Lonza, InterHealth’s ingredient portfolio complements Lonza’s existing nutritional portfolio in sports nutrition, weight management, immune health, and pet health.
The acquisition will also expand Lonza’s offerings into new areas, such as cognitive and diabetic health.
The deal is expected to close in September 2016.